As mutations do not lead to elevated non-familial cancer risk in population-based studies (except in the Li-Fraumeni syndrome families with germ-line p53 mutations), the role of single nucleotide polymorphisms (SNPs) in p53 and their association with cancer risk has been studied extensively. The gene discussed is TP53; the disease is Li-Fraumeni syndrome.